Approaching heterogeneity of human epidermal growth factor receptor 2 in surgical specimens of gastric cancer  by Asioli, Sofia et al.
www.elsevier.com/locate/humpath
Human Pathology (2012) 43, 2070–2079Original contribution
Approaching heterogeneity of human epidermal
growth factor receptor 2 in surgical specimens of
gastric cancer
Sofia Asioli MDa,1, Francesca Maletta MDa,1, Ludovica Verdun di Cantogno BSc a,
Maria A. Satolli MDb, Marina Schena MDb, Carla Pecchioni BSc a, Cristina Botta BSc a,
Luigi Chiusa MDa, Luca Molinaro MDa, Luca Conti MDa, Giuseppe Viale MDc,
Giuseppe Ingravallo MDd, Eugenio Maiorano MDd, Anna Sapino MDa,⁎
aDepartment of Biomedical Sciences and Human Oncology, University of Turin, 10126 Turin, Italy
bOnco-Haematological Department, Oncology Unit, S. Giovanni Battista Hospital, 10126 Turin, Italy
cDepartment of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, 20122 Milan, Italy
dDepartment of Pathological Anatomy, University of Bari, 70124 Bari, Italy
Received 2 January 2012; revised 17 February 2012; accepted 22 February 2012e
s
E
re
0
hKeywords:
Gastric cancer;
HER2;
Immunohistochemistry;
Surgical specimenSummary Gastric cancer shows intratumoral heterogeneity for human epidermal growth factor receptor
2 expression. We evaluated whether the number of tissue blocks analyzed or the antibodies used may
influence the immunohistochemical results in gastrectomy specimens. Clinicopathologic data from 148
patients receiving gastric surgery for cancer were collected. One tissue block for each of 88 primary
tumors and 60 paired primary tumors and metastases was examined for human epidermal growth factor
receptor 2 status by immunohistochemistry using 3 different antibodies (HercepTest, CB11, and 4B5)
and by fluorescent in situ hybridization. Two additional tissue blocks of the primary tumor were tested
by immunohistochemistry if the results were negative on the first tissue block. The concordance among
the 3 antibodies was 94.5% (testing 1 tissue block). Two cases showed a clinically significant
discrepancy between primary tumor (score 0) and lymph nodes metastases (score 3+). Additional block
analysis increased both the sensitivity (from 63% to 83%) and the accuracy (from 91% to 94%) of
immunohistochemistry as compared with fluorescent in situ hybridization. The multiblock approach
could potentially identify a greater number of human epidermal growth factor receptor 2–positive
gastric cancers, particularly those with higher levels of intratumor heterogeneity. In turn, humanAbbreviations: ToGA, Trastuzumab for Gastric Cancer; ESMO, European Society for Medical Oncology; IHC, immunohistochemistry; SISH, silver-
nhanced in situ hybridization result; FISH, ﬂuorescent in situ hybridization result; K, κ of Cohen-Fleiss; WK, weighted κ of Cohen; DSS, disease-speciﬁc
urvival; HR, hazard ratio; CI, conﬁdence interval; CT, chemotherapy; A, ampliﬁed; NA, not ampliﬁed; TP, true positive; TN, true negative.
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2071HER2 heterogeneity and gastrectomy specimensepidermal growth factor receptor 2 positivity correlated with a worse prognosis (P = .011) and was an
independent variable in multivariate analysis (hazard ratio, 1.57). In conclusion, testing more than 1
tissue block of cancer from specimens of gastric resection provides a more reliable human epidermal
growth factor receptor 2 assessment regardless of the antibody used.
© 2012 Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
In recent years, several studies have described the negative
prognostic role of human epidermal growth factor receptor
(HER) 2 overexpression in gastric cancer [1-3]. In 2010, the
“Trastuzumab for Gastric Cancer (ToGA)” study [4], a
randomized, multicenter, international, phase 3, controlled
trial was designed to assess the clinical efﬁcacy and safety of
the anti-HER2 agent trastuzumab (Herceptin; Roche, Basel,
Switzerland) as an addition to chemotherapy for ﬁrst-line
treatment of advanced or metastatic gastric cancer over-
expressing HER2 [4]. The results showed improved survival
for patients treated with trastuzumab and chemotherapy
compared with patients treated with chemotherapy alone. At
the 12th European Society for Medical Oncology/World
Congress on Gastrointestinal Cancer, it has been recom-
mended that all patients with metastatic gastric adenocarci-
noma who are candidates for ﬁrst-line chemotherapy should
be tested for HER2 status, and patients with a tumor
overexpressing HER2, as deﬁned by an immunohistochem-
ical (IHC) score of 3+ or 2+ and a conﬁrmatory silver-
enhanced (SISH) or ﬂuorescent (FISH) in situ hybridization
result, should be treated with the cisplatin/ﬂuoropyrimidine
plus trastuzumab combination [5].
At present, the rate of HER2 positivity in gastric
carcinomas varies in the literature from 6.1% to 91%
[1,4,6,7]. The HER2 status may be inﬂuenced by the
histologic type and location of the tumor or the age of the
patients. For example, Moelans et al [8] recently reported a
3% rate of HER2 expression in patients with gastric cancer
younger than 45 years. On the other hand, the discrepancy
could be the consequence of use of anti-HER2 antibodies
with different sensitivity [9] and speciﬁcity. Another cause
of the discrepancy may be the revision of the original
deﬁnition, as given by Hofmann et al [10], of the membrane
location of HER2 in overexpressing gastric cancer cells that
was a “moderate to strong complete or basolateral
membranous reactivity.” This deﬁnition was slightly
modiﬁed in the ToGA trial [4], so that “intense lateral
membrane” positivity was considered valid as well. The
different quantitative criteria used to deﬁne HER2 over-
expression in surgical samples and biopsy specimens may
be involved as well in the aforementioned discrepancy:
although the positivity of 1 cell cluster irrespective of the
size in the latter is sufﬁcient, in a surgical specimen, at least
10% of cells have to be present to be scored 3+ and
classiﬁed as overexpressing HER2 [4]. This percentagevalue may be inﬂuenced by the heterogeneity [11] of HER2
expression in large gastric cancer, so that the assessment of
HER2 in just 1 tissue block obtained from surgical
specimens of gastrectomy could produce false-negative
results. For example, Hsu et al [6] studying HER2
expression in a large case series of gastric resection for
cancer showed a rate of positive cases of 6.1%. This low rate
of HER2 expression failed to be an independent prognostic
factor at multivariate analysis. However, it is worth
mentioning that IHC tests were performed on tissue
microarrays obtained from a single parafﬁn block. Recently,
an up-to-date guidance on standardizing tissue processing,
HER2 testing, and scoring in patients with gastric cancer
remarked that HER2 results of tissue microarrays are not
suitable for clinical decision due to the heterogeneous nature
of HER2 overexpression and ampliﬁcation in this tumor
type [12].
In the present study, taking into account the possible
heterogeneity of HER2 expression, we wanted to evaluate
whether to examine a single tissue block could impair the
IHC results in surgical specimens of large gastric cancers.2. Materials and methods
2.1. Case series
Formalin-ﬁxed, parafﬁn-embedded blocks of specimens of
surgically resected gastric cancer were retrieved from the ﬁles
of the Departments of Pathology of Ospedale S. Giovanni
Battista of the University of Turin (98 cases) and of Ospedale
Policlinico of the University of Bari (50 cases), Italy.
The case series was represented by 88 samples of primary
tumor only and 60 samples of paired primary tumors and
metastases (58 metastatic lymph nodes and 2 liver
metastases). Clinicopathologic and follow-up data (disease
persistence, recurrence, and metastases) were collected for
all cases.
Institutional review board permission was obtained, and
the study was conducted in compliance with the ethical
regulatory issues of the participating institutions for the
handling of biological specimens from tumor banks, that is,
the samples exclusively available for research purposes in
retrospective studies. The number of tissue blocks sampled
for each primary tumor ranged from 4 to 8. The hematoxylin
and eosin slides were reviewed to select the block for HER2
analysis; these blocks had to show at least 50% invasive
Table 1 Clinical and pathologic features of 148 cases of
gastric cancers
Parameters Values
Age (y)
Range 34-89
Mean 69
Sex
Male 89 (60%)
Female 59 (40%)
Site
Cardia, fundus, body 71 (48%)
Antrum or pyloric 69 (46.6%)
Anastomosis 8 (5.4%)
Chemotherapy
CT 34
No CT 47
Histotype
Intestinal 97 (65%)
Diffuse 36 (24%)
Mixed 5 (3%)
Other 10 (7%)
Stage
I 15 (10%)
II 48 (32%)
III 72 (49%)
IV 13 (9%)
Grade
1 10 (7%)
2 58 (39%)
3 80 (54%)
Intestinal metaplasia
Absent 100 (68%)
Present 48 (32%)
Helicobacter pylori
Absent 132 (89%)
Present 16 (11%)
Abbreviation: CT, chemotherapy.
2072 S. Asioli et al.cancer cells in the histologic section. The same criterion was
used to select additional slides for extra HER2 IHC staining
if necessary. Given that the gross mapping of the tumor mass
was not reported, we considered the slides that did not show
normal mucosa as derived from sampling of the tumor core
and slides that showed some normal mucosa as peripheral to
the tumor mass. The histologic type, grade of each case, and
pathologic staging were reviewed according to the World
Health Organization criteria [13].
2.2. IHC tests
Sections were processed for IHC using 3 different
antibodies against the HER2 intracellular domain: 4B5 (rabbit
monoclonal antibody, prediluted; Ventana Medical Systems,
Inc, Tucson, AZ), which was applied using the BenchMark
XT automated stainer (Ventana); CB11 (prediluted, Oracle
kit; Novocastra Laboratories, Newcastle-upon-Tyne, UK),
which was applied on the Bond automated stainer (Menarini
Diagnostics, Florence, Italy); and the HercepTest kit (Dako
Denmark A/S, Glostrup, Denmark) on the Dako Autostainer.
Three pathologists (S.A., F.M., and G.I.) screened each
slide for HER2 expression according to the “magniﬁcation
rule” [14], so that, for a score of 3+, expression was detectable
at low magniﬁcation (×2.5-5); a score of 2+, at ×10 to ×20
magniﬁcation; and a score of 1+, at ×40 magniﬁcation.
Deﬁnitive IHC scoring was then performed as proposed in the
ToGA trial [4]: “score 0/negative,” no reactivity or membra-
nous reactivity in less than 10% of tumor cells; “score 1+/
negative,” faint/barely perceptible membranous reactivity in
more than 10% of tumor cells and cells that are reactive only
in part of their membranes; “score 2+/equivocal,” weak to
moderate complete, basolateral, or lateral membranous
reactivity in more than 10% of tumor cells; and “score 3+/
positive,” moderate to strong complete, basolateral, or lateral
membranous reactivity in more than 10% of tumor cells.
Samples with an IHC staining score of 0 because less than
10% of cells were positive were scanned by the automated
image analyzer D-SIGHT (Menarini Diagnostics) to conﬁrm
the percentage of positive tumor area. In all cases scored 0/1+,
HER2 expression was studied on additional blocks. The “most
positive” block was considered for the ﬁnal evaluation of
HER2 results. Discordant cases were reviewed on a multihead
microscope to reach a consensus.
2.3. FISH test
FISH was carried out using the same tissue block used
for IHC and a dual-probe HER2 (17q12) and CEP17
(centromeric probe 17) assay (Vysis, Inc, Downers Grove,
IL), according to the manufacturer's instructions as
described elsewhere [15]. The whole slide was then
screened at ×20 using an epiﬂuorescence microscope
(Zeiss, Gottingen, Germany). FISH analysis was performed
automatically by the Metafer system through the PathVy-
sion V2 classiﬁer and Isis software by MetaSystems GmbH(Altlussheim, Germany) (Food and Drug Administration
approved) and reviewed by at least 2 of the authors (L.V.
and A.S.). A HER2:CEP17 ratio greater than 2 was deﬁned
as positive for HER2 ampliﬁcation. In cases with focal
overexpression, gene ampliﬁcation was evaluated using the
D-SIGHT system (Menarini Diagnostics), which is able to
relocate the cell cluster overexpressing HER2 by IHC on
the slide tested by FISH.
2.4. Statistical analysis
Data were analyzed using Stata/SE statistical software
(version 17.0; StataCorp LT, College Station, TX). Concor-
dance among the different antibodies and between each
antibody and FISH was calculated using the Cohen-Fleiss κ
statistic (K) and the weighted κ (WK) statistic.
The cumulative survival rates were calculated by the
Kaplan-Meier method, using the date of surgery as the
Table 2 IHC results of the 3 anti-HER2 antibodies on 1 tissue block of gastric cancer and concordance between each antibody by K
and WK
No. of cases
Score 0 Score 1+ Score 2+ Score 3+
Clone 4B5 120 (81%) 10 (6.7%) 2 (1.3%) 16 (11%)
CB11 Oracle 115 (77.7%) 15 (10%) 2 (1.3%) 16 (11%)
HercepTest 114 (77%) 17 (11.5%) 2 (1.5%) 15 (10%)
K of Cohen-Fleiss 94.5% (P b .05)
Concordance between: K WK
Clone 4B5 and CB11 Oracle 96.2% 96.1%
Clone 4B5 and HercepTest 94.5% 94.2%
CB11 Oracle and HercepTest 95.6% 96.0%
2073HER2 heterogeneity and gastrectomy specimensstarting point; the follow-up period was assessed at the
time of death or at the last clinical investigation of the
patient. The disease-speciﬁc survival (DSS) was calculat-
ed from the date of deﬁnitive surgery to the date of death
from the disease. Univariate analysis was used to
examine which variables had prognostic signiﬁcance.Fig. 1 Decisional workﬂow for the assessment of HER2 by IHC on 148
3 tissue blocks is dependent on the IHC results. Multiblock approach, rese
identifying cases with heterogeneous expression of HER2.The survival differences were determined by log-rank
analysis, and the variables taken into consideration were
age, stage, grade, histotype, site and type of chemother-
apy, and IHC results of 1 block and of multiple blocks.
The relative hazards and the relative 95% conﬁdence
intervals (CIs) were calculated using the Cox proportionalsurgical specimens of gastric cancer. The decision to analyze 1, 2, or
rved to HER2-negative cases, enhances the HER2 test sensitivity by
Fig. 2 Example of relocation of image analysiswithD-SIGHT software (left, dark-ﬁeld FISH) (right, bright-ﬁeld IHC) using the 3-point alignment
method (points inside red circles). The software is able to exactly relocate, on the FISH-scanned slide, the same ﬁeld of interest selected on the IHC-
stained slides (green circles).
2074 S. Asioli et al.hazard model. A P value less than .05 was considered
statistically signiﬁcant.Fig. 3 Graphical correlation of HER2 expression, as detected on
multiple blocks with tumor topography in cases originally negative
on 1 block. In cases 5, 6, and 8, areas scored as 3+ (white triangle)
were randomly distributed within score 2+ areas (dotted rectangle).
The variance of HER2 expression was greater in tumors of groups I
and III of the classiﬁcation Goseki et al.3. Results
The clinicopathologic features of the patients are
reported in Table 1. The follow-up period for the patients
ranged from 1 to 64 months (mean, 29 months). The
therapeutic protocol was known for 81 of 98 cases of the
Turin series only. Twenty-eight patients received adjuvant
chemotherapy (ﬂuoropyrimidine) after surgery. Three
patients received neoadjuvant chemotherapy (platinum-
ﬂuoropyrimidine) before surgery. Two of these cases
showed HER2 overexpression/ampliﬁcation both on the
preoperative biopsy and on the surgical specimen, whereas
1 case was HER2 negative.
3.1. Analysis of concordances
The comparison of HER2 scores obtained using the
different antibodies did not show signiﬁcant differences
(Table 2). The 20 cases scored as 3+ were all ampliﬁed
regardless of the antibody used, whereas only 1 of the 2
cases scored 2+ was ampliﬁed. The K statistic between
the IHC results of the primary tumor and the metastases
was 79% for 4B5 and CB11 and 71% for HercepTest(P b .05). Using 4B5 and CB11, 2 cases showed a
clinically relevant discrepancy because the primary tumors
were classiﬁed as negative (score 0, because HER2
2075HER2 heterogeneity and gastrectomy specimensexpression was strong but in b10% of cells), whereas the
lymph node metastases were diffusely scored 3+. In
another 2 cases, there was a minor discrepancy because
the HER2 expression was either 3+ or 2+ in the primary
or in the metastasis, but both tumor and lymph node
metastases were ampliﬁed. The concordance between the
IHC scoring of the 3 antibodies and the FISH results was
slightly better in the metastases (82% for 4B5, 88.6% for
CB11/Oracle, and 88% for HercepTest; P b .05) than in
the primary tumors (80% for 4B5, 84% for CB11/Oracle,
and 82% for HercepTest; P b .05).Fig. 4 A, Tumor with a polypoid growth pattern initially classiﬁed as ne
area with intense membrane staining represented less than 10% of cancer
inﬁltrative growth pattern showing HER2moderate membrane staining in3.2. Analysis of negative cases (score 0/1+)
To evaluate whether the assessment of HER2 using more
than 1 block could rescue some of the 126 cases that tested
negative (0/1+) with at least 2 of the antibodies, additional
tissue blocks were processed for IHC analysis as shown in
the workﬂow (Fig. 1) using the Oracle Kit.
Using 1 block, 100 cases were scored 0 (67.6%) because
no immunostaining of tumor cells was observed; 2 of these
cases were ampliﬁed either focally (1 case) or diffusely (1
case) by FISH. Fifteen cases were scored 1+, and all of themgative using a single block evaluated using D-SIGHT. B and C, The
cells (score 0) and Goseki group I. D-E, An example of tumor with
less than 10% of cancer cells in an area classiﬁed as Goseki group III.
Fig. 5 Gastric carcinoma with signet ring features (group IV of
Goseki classiﬁcation) positive for HER2 (score 3+).
2076 S. Asioli et al.were not ampliﬁed by FISH. Eleven cases (7.4%) were
scored as negative because the percentage of 2+/3+ tumor
cells was greater than 10%. The automated evaluation of the
score and percentage of positive cells of these 11 cases
conﬁrmed the semiquantitative analysis performed by
conventional microscopy. The cell clusters deemed positive
by IHC were also ampliﬁed by FISH, which was conﬁrmed
using the image analyzer D-SIGHT (Fig. 2), which is able to
relocate precisely on the dark ﬁeld (FISH) the area selected
on the bright ﬁeld (IHC).
The IHC score shifted from negative to 2+/3+ in 5 cases
using 1 additional block and in 6 further cases using another
extra block (Fig. 1). FISH analysis was repeated in the 3
cases that showed equivocal (2+) HER2 results in the
additional blocks. One of these was ampliﬁed. The single
case that was classiﬁed as diffusely HER2 ampliﬁed by FISH
and IHC negative (score 0) remained IHC negative in the
additional block. To evaluate whether technical biases
related to processing of gastrectomy specimens (eg, poor
ﬁxation) were the cause of this result, we analyzed HER2 in
the preoperative biopsy of the same patient, which was
ampliﬁed by FISH but HER2 negative by IHC as well.
The HER2 variance of the cases that were initially
classiﬁed as negative using a single block was then correlated
with tumor topography and with an at least rough sectorialTable 3 Sensitivity, speciﬁcity, and accuracy of immunohistochemistr
or 2 tissue blocks in negative cases (score 0/1+)
Sensitivity Specificity
% (TP/A) CI (95%) % (TN/NA)
1 block 63.63 (21/33) 45.14-79.04 99.13 (114/115
2 blocks 73.53 (25/34) 55.35-86.49 98.25 (112/114
3 blocks 83.33 (30/36) 66.53-93.04 97.32 (109/112
Abbreviations: TP, true positive (IHC score 2+/3+ and FISH ampliﬁed); A, ampli
not ampliﬁed cases.mapping (eg, tumor center versus advancing edge) as
reproduced in Fig. 3. One of these tumors had a polypoid
growth (Fig. 4A-C), whereas all the others had an inﬁltrative
growth (Fig. 4D and E). HER2 expression was generally
randomly distributed in the tumor with a not-signiﬁcant
prevalence of superﬁcial area as compared with the
inﬁltrative deep edges. In some cases, the heterogeneity
was not only related to the topographic distribution but also to
the different intensity of the staining, with score 3+ foci being
randomly distributed within score 2+ areas (Fig. 3, cases 5, 6,
and 8). The correlation using the Goseki classiﬁcation [16]
showed that the variance of HER2 expression was greater in
tumor showing tubular differentiation and low mucus
accumulation (groups I and III) (Fig. 3). Two cases of the
diffuse type with signet ring feature (group IV) were positive
on the ﬁrst block (Fig. 5). No correlation with nuclear pleo-
morphism or mitoses and HER2 expression was observed.
3.3. Sensitivity, specificity, and accuracy between
IHC and FISH
The sensitivity, speciﬁcity, and accuracy of the IHC
testing of all 148 cases compared with the FISH analysis
were then recalculated using the results obtained by testing 2
or 3 tissue blocks of the cases that were negative on the ﬁrst
block. Considering FISH to be the criterion standard, the
addition of further blocks to the HER2 evaluation increased
both the sensitivity and accuracy of the IHC results, whereas
the speciﬁcity decreased if cases with 2+ scores were
supposed to be ampliﬁed (Table 3).
3.4. Clinical correlation
The univariate analysis (Table 4) showed a signiﬁcant
correlation for age, stage, grade, and IHC results performed
on multiple blocks with DSS. The Kaplan-Meier analysis did
not show any signiﬁcant correlation (P = .71) for the results
obtained using a single block to deﬁne HER2-negative status
and DSS (Fig. 6A); on the contrary (Fig. 6B), HER2
positivity was signiﬁcantly (P = .011) correlated with a
worse prognosis when assessed using multiple blocks.
Multivariate Cox regression analysis conﬁrmed that
HER2 expression, as deﬁned by the examination of multipley (compared with FISH) in 148 cases of gastric cancer by adding 1
Accuracy
95% CI % (TP + TN/total) 95% CI
) 94.54-99.95 91.22 (135/148) 85.15-95.05
) 93.18-99.69 92.57 (137/148) 86.77-96.05
) 91.79-99.31 93.91 (139/148) 88.43-97
ﬁed cases; TN, true negative (IHC score 0/1+ and FISH not ampliﬁed); NA,
Table 4 Univariate analysis of clinical and pathologic data correlated with DSS
n Events Mean DSS 95% CI χ2 P
Age b70 y 67 28 48.52 43.49-53.55 4.279 .039
≥70 y 81 36 40.27 34.55-46.00
Stage I 15 2 54.62 45.09-64.16 11.38 .01
II 48 12 48.91 41.85-55.98
III 72 39 41.72 36.09-47.35
IV 13 11 37.03 27.38-46.68
Grade I 10 1 63.00 63.00-63.00 6.186 .045
II 58 21 42.86 36.08-49.27
III 80 42 42.51 37.27-47.76
Histotype Intestinal 97 34 44.00 38.95-49.06 5.63 .13
Diffuse 36 25 41.03 33.37-48.69
Mixed 5 2 30.62 13.66-47.59
Other 10 3 59.66 52.12-62.12
Site Cardia, fundus, body 71 28 42.82 36.99-48.65 0.722 .697
Antrum, pylorus 69 34 44.62 39.05-50.20
Anastomosis 8 2 46.00 18.56-73.44
Chemotherapy No 47 20 31.19 23.74-38.65 1.959 .162
Yes 34 12 38.30 30.04-46.57
IHC with 1 block IHC score 0-1-2NA 127 54 44.54 40.31-48.77 0.134 .71
IHC score 2A-3 21 10 42.50 32.13-52.87
IHC with new protocol IHC score 0-1-2NA 118 46 46.89 42.66-51.12 6.436 .011
IHC score 2A-3 30 18 34.67 26.07-43.27
Abbreviations: NA, not ampliﬁed; A, ampliﬁed.
2077HER2 heterogeneity and gastrectomy specimensblocks, was an independent variable for prognosis (hazard
ratio [HR], 1.572; 95% CI, 1.195-2.112; P = .001), together
with the age of patients (HR, 1.986; 95% CI, 1.187-3.324;
P = .009), the disease stage (HR, 1.749; 95% CI, 1.2-2.549;
P = .004), and the grade (HR, 2.797; 95% CI, 1.018-7.682;
P = .046) of gastric cancer.Fig. 6 Kaplan-Meier estimates of DSS (in months) according to HER2
specimens of gastric cancer. Abbreviations: NA, not ampliﬁed; A, ampli4. Discussion
Previous studies have described HER2 expression
heterogeneity as a frequent event in gastric cancer
[7,10,17,18]. In breast cancer, the intratumor heterogeneity
of the HER2 gene is deﬁned as a tumor showing more thanstatus assessed using 1 block (A) and multiple blocks (B) of surgical
ﬁed.
2078 S. Asioli et al.5% but less than 50% of inﬁltrating cells, with a ratio higher
than 2.2 by FISH and the incidence ranging from 5% to 30%
[19]. In gastric carcinoma, the intratumor heterogeneity has
yet to be speciﬁcally deﬁned. For example, in a recent work,
Lee et al [20] focusing on IHC 3+ or IHC 2+⁄SISH-positive
tumors determined that negative or not uniform weakly
stained areas were present in 50% of the surgical and in 42%
of biopsy specimens, respectively. Boers et al [9] stated that
the number of positive fragments and/or of calculated H-
score did not predict ampliﬁcation status in 73% of biopsy
specimens due to heterogeneity of HER2 expression of
gastric adenocarcinomas.
In the present work, we assessed heterogeneity in a series
of 126 gastric cancers, of 148 surgically resected, that were
negative at the IHC analyses performed using different
antibodies on 1 tissue block. We can exclude a signiﬁcant
inﬂuence for the antibody's selection if the IHC procedures
are adequately performed [12] and if the scoring follows
strict rules [10,14]. On the other hand, in our case series,
inadequate sample selection produced 7.1% of false-negative
results. This suggests that the HER2 IHC analysis of a single
block of the primary tumor could not be sufﬁciently
conﬁdent to compensate for the heterogeneity of HER2
expression in a large gastric cancer. For example, in the
present series, the mean size of the tumor was around 5.5 cm.
Using a single block, 14% of gastric cancers were positive,
whereas the addition of further blocks increased the rate to
20%, a value that was slightly higher than that obtained by
Hofmann et al [10] using 1 block (17%). However, the
analysis of 3 tissue blocks increased the positive rate to
approximately 50% of the cases overexpressing HER2 but
scored as negative because the percentage of positive cells
was less than 10% in a single block. In our series, only 1
(0.7%) of 148 case was diffusely ampliﬁed by FISH and
constantly negative by IHC, whereas 9 ampliﬁed cases were
rescued from IHC negative to positive by testing at least 3
blocks. The accuracy of IHC, as compared with FISH,
increased from 91% to about 94% using multiple-block
analysis. In the recently published guidelines on HER2 in
gastric cancer [12], it is suggested that for surgical specimen
cases with strong HER2 staining in less than 10% of cells,
retesting with ISH may be warranted. If such a sample is
FISH-SISH positive, the tumor may be considered to be
HER2 positive similar to the scoring on biopsy samples [12].
Heterogeneity may also lead to discrepancies between
primary tumors and metastases. For example, in the present
work, we showed a clinically relevant difference in 2 cases
that were scored 0 (not eligible for trastuzumab therapy) in
the primary tumor because of the low percentage of HER2-
positive cells and scored 3+ in the metastatic lymph node
(eligible for trastuzumab).
The hypothesis that the level of HER2 protein might
inﬂuence the response to trastuzumab was investigated in a
post hoc analysis of the ToGA trial [4]; this analysis revealed
a signiﬁcant increase in the response to trastuzumab in the
subgroup with high HER2 expression. However, somebeneﬁts were also achieved by treating patients with HER2
gene ampliﬁcation by FISH and protein negativity by IHC.
The underlying explanations for these results have not been
fully evaluated. We demonstrated that multisampling detec-
tion of HER2 expression could potentially identify cases with
higher levels of intratumor heterogeneity, which may be
associated with adverse outcomes but, in turn, could have a
therapeutic advantage from trastuzumab treatment. As a
matter of fact, HER2 positivity correlated with a worse
prognosis and was an independent variable in multivariate
analysis only when assessed using multiple blocks. These
results seem biologically more reliable than those reported by
others [6] on tissue microarrays obtained from a single
parafﬁn block, where a lower HER2 expression failed to be an
independent prognostic factor.
Thus, if the HER2 test is performed on surgical samples
of gastric carcinoma, the results may be inﬂuenced by the
tissue block more than by the antibody selection. Gastric
tumors at diagnosis are generally larger than breast tumors,
and the analysis of a single block may not compensate for the
possible intratumor heterogeneity. Particularly, when the
HER2 overexpressing cells are focally present, more than 1
tissue block should be tested by IHC.
In conclusion, the workﬂow we propose (Fig. 1), while
producing a relatively higher workload for pathologists,
increases the accuracy of the HER2 testing in gastric cancer.References
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